JP7343571B2 - マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 - Google Patents

マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 Download PDF

Info

Publication number
JP7343571B2
JP7343571B2 JP2021514292A JP2021514292A JP7343571B2 JP 7343571 B2 JP7343571 B2 JP 7343571B2 JP 2021514292 A JP2021514292 A JP 2021514292A JP 2021514292 A JP2021514292 A JP 2021514292A JP 7343571 B2 JP7343571 B2 JP 7343571B2
Authority
JP
Japan
Prior art keywords
compound
hydrogen
alkyl
pharmaceutically acceptable
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523241A5 (https=
JP2021523241A (ja
JPWO2019222157A5 (https=
Inventor
ヤン，ウェンジン
チャン，カイ－ウェイ
リュー，スイン
ツァイ，チェン－ハン
Original Assignee
フォアシー ファーマシューティカルズ ユーエスエー，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フォアシー ファーマシューティカルズ ユーエスエー，インコーポレーテッド filed Critical フォアシー ファーマシューティカルズ ユーエスエー，インコーポレーテッド
Publication of JP2021523241A publication Critical patent/JP2021523241A/ja
Publication of JP2021523241A5 publication Critical patent/JP2021523241A5/ja
Publication of JPWO2019222157A5 publication Critical patent/JPWO2019222157A5/ja
Priority to JP2023140718A priority Critical patent/JP2023164905A/ja
Application granted granted Critical
Publication of JP7343571B2 publication Critical patent/JP7343571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021514292A 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 Active JP7343571B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023140718A JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671753P 2018-05-15 2018-05-15
US62/671,753 2018-05-15
PCT/US2019/032131 WO2019222157A1 (en) 2018-05-15 2019-05-14 Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023140718A Division JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Publications (4)

Publication Number Publication Date
JP2021523241A JP2021523241A (ja) 2021-09-02
JP2021523241A5 JP2021523241A5 (https=) 2022-03-15
JPWO2019222157A5 JPWO2019222157A5 (https=) 2022-03-15
JP7343571B2 true JP7343571B2 (ja) 2023-09-12

Family

ID=66690981

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2021514292A Active JP7343571B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2021514291A Active JP7344959B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2023140718A Pending JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2023142664A Active JP7656669B2 (ja) 2018-05-15 2023-09-04 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021514291A Active JP7344959B2 (ja) 2018-05-15 2019-05-14 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2023140718A Pending JP2023164905A (ja) 2018-05-15 2023-08-31 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP2023142664A Active JP7656669B2 (ja) 2018-05-15 2023-09-04 マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Country Status (20)

Country Link
US (6) US20190352288A1 (https=)
EP (4) EP4335499A3 (https=)
JP (4) JP7343571B2 (https=)
KR (3) KR102861502B1 (https=)
CN (3) CN112424186A (https=)
AU (3) AU2019269409B2 (https=)
BR (1) BR112020023269A2 (https=)
CA (2) CA3100320A1 (https=)
DK (2) DK3793995T3 (https=)
ES (2) ES2978192T3 (https=)
FI (2) FI3793992T3 (https=)
HU (2) HUE066619T2 (https=)
LT (1) LT3793995T (https=)
MY (1) MY199200A (https=)
PL (1) PL3793995T3 (https=)
PT (2) PT3793992T (https=)
SG (2) SG11202011316RA (https=)
SI (1) SI3793995T1 (https=)
TW (3) TWI827601B (https=)
WO (2) WO2019222157A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023164905A (ja) * 2018-05-15 2023-11-14 フォアシー ファーマシューティカルズ ユーエスエー，インコーポレーテッド マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CA3158234A1 (en) * 2019-11-14 2021-05-20 Foresee Pharmaceuticals Co., Ltd. Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
EP4351566A4 (en) * 2021-06-08 2025-04-23 Foresee Pharmaceuticals USA, Inc. SAFE ADMINISTRATION OF MMP-12 INHIBITOR
TW202313011A (zh) * 2021-06-08 2023-04-01 逸達生物科技股份有限公司 Mmp抑制劑於治療急性呼吸窘迫綜合症之用途
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023110473A1 (en) 2021-12-14 2023-06-22 Basf Se Heterocyclic compounds for the control of invertebrate pests

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067996A1 (en) 2002-10-04 2004-04-08 James Sheppeck Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
JP2008510701A (ja) 2004-08-19 2008-04-10 クエスト ファーマシューティカル サーヴィシーズ マクロファージエラスターゼの阻害剤としての５−［３−（４−ベンジルオキシフェニルチオ）−フラ−２−イル］−イミダゾリジン−２，４−ジオン及び類似体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482618A1 (fr) 1980-05-16 1981-11-20 Inst Corps Gras Iterg Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
EP1150975A1 (en) 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
EP1288199A4 (en) 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
JP2004527511A (ja) 2001-03-15 2004-09-09 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼ阻害剤
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
EP1394159A1 (fr) 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
EP2797002A4 (en) 2011-12-21 2015-05-20 Panasonic Corp DATA PROCESSING DEVICE, DATA TRANSMISSION DEVICE, DATA PROCESSING SYSTEM, DATA PROCESSING METHOD AND DATA TRANSMISSION METHOD
SI3793995T1 (sl) * 2018-05-15 2024-05-31 Foresee Pharmaceuticals Usa, Inc. Zaviralci matrične metaloproteinaze (mmp)in načini njihove uporabe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067996A1 (en) 2002-10-04 2004-04-08 James Sheppeck Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
JP2008510701A (ja) 2004-08-19 2008-04-10 クエスト ファーマシューティカル サーヴィシーズ マクロファージエラスターゼの阻害剤としての５−［３−（４−ベンジルオキシフェニルチオ）−フラ−２−イル］−イミダゾリジン−２，４−ジオン及び類似体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY STN Online, 2008, RN 1061319-03-6，2008年，RN 1061319-03-6

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023164905A (ja) * 2018-05-15 2023-11-14 フォアシー ファーマシューティカルズ ユーエスエー，インコーポレーテッド マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法

Also Published As

Publication number Publication date
CN112424192A (zh) 2021-02-26
AU2019269409B2 (en) 2023-11-23
EP3793995A1 (en) 2021-03-24
FI3793992T3 (fi) 2024-04-17
TW202003493A (zh) 2020-01-16
EP3793992A1 (en) 2021-03-24
EP4335499A3 (en) 2024-05-15
KR20210020011A (ko) 2021-02-23
TW202002975A (zh) 2020-01-16
HUE066619T2 (hu) 2024-08-28
AU2019269409A1 (en) 2021-01-07
SG11202011318QA (en) 2020-12-30
EP4335499A2 (en) 2024-03-13
PT3793992T (pt) 2024-05-13
TW202400584A (zh) 2024-01-01
CA3100320A1 (en) 2019-11-21
US20240018131A1 (en) 2024-01-18
KR20250021604A (ko) 2025-02-13
BR112020023269A2 (pt) 2021-02-23
JP2023164905A (ja) 2023-11-14
KR20210020897A (ko) 2021-02-24
SI3793995T1 (sl) 2024-05-31
ES2984594T3 (es) 2024-10-30
WO2019222154A1 (en) 2019-11-21
TWI895726B (zh) 2025-09-01
JP7344959B2 (ja) 2023-09-14
US12258335B1 (en) 2025-03-25
CN112424186A (zh) 2021-02-26
HUE066627T2 (hu) 2024-08-28
PT3793995T (pt) 2024-05-02
PL3793995T3 (pl) 2024-05-06
AU2019270975B2 (en) 2023-12-14
AU2024200323B2 (en) 2025-06-05
EP4349332A2 (en) 2024-04-10
US20210214340A1 (en) 2021-07-15
US20190352288A1 (en) 2019-11-21
US11739080B2 (en) 2023-08-29
AU2019270975A1 (en) 2021-01-07
MY199200A (en) 2023-10-19
DK3793995T3 (da) 2024-04-08
US12215096B2 (en) 2025-02-04
JP7656669B2 (ja) 2025-04-03
EP4349332A3 (en) 2024-05-15
AU2024200323A1 (en) 2024-02-01
SG11202011316RA (en) 2020-12-30
CN119462623A (zh) 2025-02-18
JP2021523241A (ja) 2021-09-02
TWI798435B (zh) 2023-04-11
US10851089B2 (en) 2020-12-01
US20250115590A1 (en) 2025-04-10
TWI827601B (zh) 2024-01-01
ES2978192T3 (es) 2024-09-06
JP2023164924A (ja) 2023-11-14
CN112424192B (zh) 2024-11-26
CA3100319A1 (en) 2019-11-21
US20190352287A1 (en) 2019-11-21
LT3793995T (lt) 2024-04-25
KR102761591B1 (ko) 2025-01-31
EP3793995B1 (en) 2024-01-10
WO2019222157A1 (en) 2019-11-21
KR102861502B1 (ko) 2025-09-18
EP3793992B1 (en) 2024-01-10
JP2021523240A (ja) 2021-09-02
DK3793992T3 (da) 2024-04-08
FI3793995T3 (fi) 2024-04-17

Similar Documents

Publication Publication Date Title
JP7343571B2 (ja) マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
JP5898230B2 (ja) Ｓ−ニトロソグルタチオンレダクターゼ阻害薬としての新規な置換二環芳香族化合物
RU2820540C2 (ru) Ингибиторы матриксной металлопротеиназы (mmp) и способы их применения
HK40050772B (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
HK40050772A (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
RU2797558C2 (ru) Ингибиторы матриксной металлопротеиназы (mmp) и способы их применения
JP7653986B2 (ja) マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
HK40107395A (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
HK40050775A (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
HK40050775B (en) Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230531

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230801

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230831

R150 Certificate of patent or registration of utility model

Ref document number: 7343571

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150